Related Experiment Videos
Tumor-associated antigens: from discovery to immunity
Jennifer D Lewis1, Brian D Reilly, Robert K Bright
1Department of Microbiology and Immunology and the Southwest Cancer Center, Texas Tech University Health Sciences Center, Lubbock, Texas 79430, USA.
International Reviews of Immunology
|September 10, 2003
Summary
Therapeutic cancer vaccines are evolving from whole-cell approaches to defined tumor-associated antigens (TAAs). Research focuses on identifying TAAs and developing novel delivery strategies for effective cancer treatment.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Early cancer vaccines utilized whole tumor cells or lysates, yielding limited therapeutic success.
- This necessitated the development of more targeted approaches for cancer immunotherapy.
Purpose of the Study:
- To review the shift towards next-generation cancer vaccines based on defined tumor-associated antigens (TAAs).
- To highlight ongoing research in TAA identification and therapeutic vaccine delivery strategies.
Main Methods:
- Review of historical and current research in cancer vaccine development.
- Focus on the definition and characterization of tumor-associated antigens (TAAs).
Main Results:
- Limited efficacy of early whole-cell tumor vaccines.
- Significant research efforts directed towards TAAs for improved cancer immunotherapy.
Conclusions:
- Renewed enthusiasm exists for therapeutic cancer vaccination.
- Continued research in TAA discovery and novel vaccine delivery is crucial for advancing cancer treatment.